Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 4 March 1994:
Vol. 263. no. 5151, pp. 1281 - 1284
DOI: 10.1126/science.8122112
Prev | Table of Contents | Next

Articles

Science, Vol 263, Issue 5151, 1281-1284
Copyright © 1994 by American Association for the Advancement of Science

articles

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

SW Morris, MN Kirstein, MB Valentine, KG Dittmer, DN Shapiro, DL Saltman, and AT Look

Department of Experimental Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105.

The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23. In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK). Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases. Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells.
C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle (2009)
Cancer Res. 69, 8611-8619
   Abstract »    Full Text »    PDF »
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology.
L. Brugieres, H. Pacquement, M.-C. Le Deley, G. Leverger, P. Lutz, C. Paillard, A. Baruchel, D. Frappaz, B. Nelken, L. Lamant, et al. (2009)
J. Clin. Oncol. 27, 5056-5061
   Abstract »    Full Text »    PDF »
Inhibition of ALK Signaling for Cancer Therapy.
Y. P. Mosse, A. Wood, and J. M. Maris (2009)
Clin. Cancer Res. 15, 5609-5614
   Abstract »    Full Text »    PDF »
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.
G. Sozzi, M. P. Martelli, D. Conte, P. Modena, V. Pettirossi, S. A. Pileri, and B. Falini (2009)
Haematologica 94, 1307-1311
   Abstract »    Full Text »    PDF »
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers.
E. Lin, L. Li, Y. Guan, R. Soriano, C. S. Rivers, S. Mohan, A. Pandita, J. Tang, and Z. Modrusan (2009)
Mol. Cancer Res. 7, 1466-1476
   Abstract »    Full Text »    PDF »
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.
M. S. Lim, M. L. Carlson, D. K. Crockett, G. C. Fillmore, D. R. Abbott, O. F. Elenitoba-Johnson, S. R. Tripp, G. Z. Rassidakis, L. J. Medeiros, P. Szankasi, et al. (2009)
Blood 114, 1585-1595
   Abstract »    Full Text »    PDF »
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population.
S. J. Rodig, M. Mino-Kenudson, S. Dacic, B. Y. Yeap, A. Shaw, J. A. Barletta, H. Stubbs, K. Law, N. Lindeman, E. Mark, et al. (2009)
Clin. Cancer Res. 15, 5216-5223
   Abstract »    Full Text »    PDF »
IL-21 Contributes to JAK3/STAT3 Activation and Promotes Cell Growth in ALK-Positive Anaplastic Large Cell Lymphoma.
J. Dien Bard, P. Gelebart, M. Anand, Z. Zak, S. A. Hegazy, H. M. Amin, and R. Lai (2009)
Am. J. Pathol. 175, 825-834
   Abstract »    Full Text »    PDF »
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
P. Shi, R. Lai, Q. Lin, A. S. Iqbal, L. C. Young, L. W. Kwak, R. J. Ford, and H. M. Amin (2009)
Blood 114, 360-370
   Abstract »    Full Text »    PDF »
Analysis of Human T-Cell Lymphotropic Virus in CD25+ Anaplastic Large Cell Lymphoma in Children.
G. Gualco, L. Chioato, L. M. Weiss, W. J. Harrington Jr, and C. E. Bacchi (2009)
Am J Clin Pathol 132, 28-33
   Abstract »    Full Text »    PDF »
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.
B. Falini and M. P. Martelli (2009)
Haematologica 94, 897-900
   Full Text »    PDF »
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
P. Bonvini, E. Zorzi, L. Mussolin, G. Monaco, M. Pigazzi, G. Basso, and A. Rosolen (2009)
Haematologica 94, 944-955
   Abstract »    Full Text »    PDF »
NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.
Y.-X. Cui, A. Kerby, F. K. E. McDuff, H. Ye, and S. D. Turner (2009)
Blood 113, 5217-5227
   Abstract »    Full Text »    PDF »
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer.
K. Takeuchi, Y. L. Choi, Y. Togashi, M. Soda, S. Hatano, K. Inamura, S. Takada, T. Ueno, Y. Yamashita, Y. Satoh, et al. (2009)
Clin. Cancer Res. 15, 3143-3149
   Abstract »    Full Text »    PDF »
Therapeutic Implications of ALK Mutations in Neuroblastoma.
R. E. George and A. Thomas Look (2009)
Am. Assoc. Cancer Res. Educ. Book 2009, 113-115
   Full Text »    PDF »
Unraveling ALK signaling through phosphoproteomics.
M. S. Lim (2009)
Blood 113, 2615-2616
   Full Text »    PDF »
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
M. G. Cornejo, M. G. Kharas, M. B. Werneck, S. L. Bras, S. A. Moore, B. Ball, M. Beylot-Barry, S. J. Rodig, J. C. Aster, B. H. Lee, et al. (2009)
Blood 113, 2746-2754
   Abstract »    Full Text »    PDF »
Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry.
F. Wu, P. Wang, L. C. Young, R. Lai, and L. Li (2009)
Am. J. Pathol. 174, 361-370
   Abstract »    Full Text »    PDF »
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues.
M. P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, et al. (2009)
Am. J. Pathol. 174, 661-670
   Abstract »    Full Text »    PDF »
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
M. Marzec, Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, et al. (2008)
PNAS 105, 20852-20857
   Abstract »    Full Text »    PDF »
The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation.
C. Ambrogio, C. Voena, A. D. Manazza, C. Martinengo, C. Costa, T. Kirchhausen, E. Hirsch, G. Inghirami, and R. Chiarle (2008)
Cancer Res. 68, 8899-8907
   Abstract »    Full Text »    PDF »
Rapid Method for Detection of Mutations in the Nucleophosmin Gene in Acute Myeloid Leukemia.
T. S. Laughlin, M. W. Becker, J. L. Liesveld, D. A. Mulford, C. N. Abboud, P. Brown, and P. G. Rothberg (2008)
J. Mol. Diagn. 10, 338-345
   Abstract »    Full Text »    PDF »
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer.
J. P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. J. Holmes, H. G. Choi, J. Kim, D. Chiang, R. Thomas, et al. (2008)
Clin. Cancer Res. 14, 4275-4283
   Abstract »    Full Text »    PDF »
Ribosomal Protein S9 Is a Novel B23/NPM-binding Protein Required for Normal Cell Proliferation.
M. S. Lindstrom and Y. Zhang (2008)
J. Biol. Chem. 283, 15568-15576
   Abstract »    Full Text »    PDF »
Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors.
U. McDermott, A. J. Iafrate, N. S. Gray, T. Shioda, M. Classon, S. Maheswaran, W. Zhou, H. G. Choi, S. L. Smith, L. Dowell, et al. (2008)
Cancer Res. 68, 3389-3395
   Abstract »    Full Text »    PDF »
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases.
A. Pierce, R. D. Unwin, C. A. Evans, S. Griffiths, L. Carney, L. Zhang, E. Jaworska, C.-F. Lee, D. Blinco, M. J. Okoniewski, et al. (2008)
Mol. Cell. Proteomics 7, 853-863
   Abstract »    Full Text »    PDF »
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al. (2008)
Blood 111, 4797-4808
   Abstract »    Full Text »    PDF »
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.
P. Sportoletti, S. Grisendi, S. M. Majid, K. Cheng, J. G. Clohessy, A. Viale, J. Teruya-Feldstein, and P. P. Pandolfi (2008)
Blood 111, 3859-3862
   Abstract »    Full Text »    PDF »
Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase.
C. J. Tartari, R. H. Gunby, A. M. L. Coluccia, R. Sottocornola, B. Cimbro, L. Scapozza, A. Donella-Deana, L. A. Pinna, and C. Gambacorti-Passerini (2008)
J. Biol. Chem. 283, 3743-3750
   Abstract »    Full Text »    PDF »
Shuttling Imbalance of MLF1 Results in p53 Instability and Increases Susceptibility to Oncogenic Transformation.
N. Yoneda-Kato and J.-y. Kato (2008)
Mol. Cell. Biol. 28, 422-434
   Abstract »    Full Text »    PDF »
Oncogene addiction: setting the stage for molecularly targeted cancer therapy.
S. V. Sharma and J. Settleman (2007)
Genes & Dev. 21, 3214-3231
   Abstract »    Full Text »    PDF »
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al. (2007)
Blood 110, 3374-3383
   Abstract »    Full Text »    PDF »
Pathobiology of ALK+ anaplastic large-cell lymphoma.
H. M. Amin and R. Lai (2007)
Blood 110, 2259-2267
   Abstract »    Full Text »    PDF »
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
A. Galietta, R. H. Gunby, S. Redaelli, P. Stano, C. Carniti, A. Bachi, P. W. Tucker, C. J. Tartari, C.-J. Huang, E. Colombo, et al. (2007)
Blood 110, 2600-2609
   Abstract »    Full Text »    PDF »
Anaplastic Lymphoma Kinase Is Activated Through the Pleiotrophin/Receptor Protein-tyrosine Phosphatase beta/{zeta} Signaling Pathway: AN ALTERNATIVE MECHANISM OF RECEPTOR TYROSINE KINASE ACTIVATION.
P. Perez-Pinera, W. Zhang, Y. Chang, J. A. Vega, and T. F. Deuel (2007)
J. Biol. Chem. 282, 28683-28690
   Abstract »    Full Text »    PDF »
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
V. Leventaki, E. Drakos, L. J. Medeiros, M. S. Lim, K. S. Elenitoba-Johnson, F. X. Claret, and G. Z. Rassidakis (2007)
Blood 110, 1621-1630
   Abstract »    Full Text »    PDF »
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
P. Brown, E. McIntyre, R. Rau, S. Meshinchi, N. Lacayo, G. Dahl, T. A. Alonzo, M. Chang, R. J. Arceci, and D. Small (2007)
Blood 110, 979-985
   Abstract »    Full Text »    PDF »
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma.
C. Damm-Welk, K. Busch, B. Burkhardt, J. Schieferstein, S. Viehmann, I. Oschlies, W. Klapper, M. Zimmermann, J. Harbott, A. Reiter, et al. (2007)
Blood 110, 670-677
   Abstract »    Full Text »    PDF »
Multisite Phosphorylation of Nuclear Interaction Partner of ALK (NIPA) at G2/M Involves Cyclin B1/Cdk1.
F. Bassermann, C. von Klitzing, A. L. Illert, S. Munch, S. W. Morris, M. Pagano, C. Peschel, and J. Duyster (2007)
J. Biol. Chem. 282, 15965-15972
   Abstract »    Full Text »    PDF »
The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration.
C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle (2007)
Cancer Res. 67, 4278-4286
   Abstract »    Full Text »    PDF »
CD30 Activates Both the Canonical and Alternative NF-{kappa}B Pathways in Anaplastic Large Cell Lymphoma Cells.
C. W. Wright, J. M. Rumble, and C. S. Duckett (2007)
J. Biol. Chem. 282, 10252-10262
   Abstract »    Full Text »    PDF »
Evaluation of Enrichment Techniques for Mass Spectrometry: Identification of Tyrosine Phosphoproteins in Cancer Cells.
J. A. Schumacher, D. K. Crockett, K. S.J. Elenitoba-Johnson, and M. S. Lim (2007)
J. Mol. Diagn. 9, 169-177
   Abstract »    Full Text »    PDF »
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli (2007)
Haematologica 92, 519-532
   Abstract »    Full Text »    PDF »
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
L. Lamant, A. d. Reynies, M.-M. Duplantier, D. S. Rickman, F. Sabourdy, S. Giuriato, L. Brugieres, P. Gaulard, E. Espinos, and G. Delsol (2007)
Blood 109, 2156-2164
   Abstract »    Full Text »    PDF »
Activation of Peroxisome Proliferator-Activated Receptor {gamma} Contributes to the Survival of T Lymphoma Cells by Affecting Cellular Metabolism.
C. Yang, S.-H. Jo, B. Csernus, E. Hyjek, Y. Liu, A. Chadburn, and Y. L. Wang (2007)
Am. J. Pathol. 170, 722-732
   Abstract »    Full Text »    PDF »
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci (2007)
Blood 109, 874-885
   Abstract »    Full Text »    PDF »
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?.
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield (2007)
Blood 109, 431-448
   Abstract »    Full Text »    PDF »
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
A. V. Galkin, J. S. Melnick, S. Kim, T. L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, et al. (2007)
PNAS 104, 270-275
   Abstract »    Full Text »    PDF »
Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action.
M. A. Garcia, J. Gil, I. Ventoso, S. Guerra, E. Domingo, C. Rivas, and M. Esteban (2006)
Microbiol. Mol. Biol. Rev. 70, 1032-1060
   Abstract »    Full Text »    PDF »
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.
L. Qiu, R. Lai, Q. Lin, E. Lau, D. M. Thomazy, D. Calame, R. J. Ford, L. W. Kwak, R. A. Kirken, and H. M. Amin (2006)
Blood 108, 2407-2415
   Abstract »    Full Text »    PDF »
Peroxisome Proliferator-Activated Receptor {gamma} Promotes Lymphocyte Survival through Its Actions on Cellular Metabolic Activities.
S.-H. Jo, C. Yang, Q. Miao, M. Marzec, M. A. Wasik, P. Lu, and Y. L. Wang (2006)
J. Immunol. 177, 3737-3745
   Abstract »    Full Text »    PDF »
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
L. Quintanilla-Martinez, S. Pittaluga, C. Miething, M. Klier, M. Rudelius, T. Davies-Hill, N. Anastasov, A. Martinez, A. Vivero, J. Duyster, et al. (2006)
Blood 108, 2029-2036
   Abstract »    Full Text »    PDF »
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage..
J. Mourali, A. Benard, F. C. Lourenco, C. Monnet, C. Greenland, C. Moog-Lutz, C. Racaud-Sultan, D. Gonzalez-Dunia, M. Vigny, P. Mehlen, et al. (2006)
Mol. Cell. Biol. 26, 6209-6222
   Abstract »    Full Text »    PDF »
Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma..
F. Vega, L. J. Medeiros, V. Leventaki, C. Atwell, J. H. Cho-Vega, L. Tian, F.-X. Claret, and G. Z. Rassidakis (2006)
Cancer Res. 66, 6589-6597
   Abstract »    Full Text »    PDF »
Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.
K. S. J. Elenitoba-Johnson, D. K. Crockett, J. A. Schumacher, S. D. Jenson, C. M. Coffin, A. L. Rockwood, and M. S. Lim (2006)
PNAS 103, 7402-7407
   Abstract »    Full Text »    PDF »
Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM Mutant..
E. Colombo, P. Martinelli, R. Zamponi, D. C. Shing, P. Bonetti, L. Luzi, S. Volorio, L. Bernard, G. Pruneri, M. Alcalay, et al. (2006)
Cancer Res. 66, 3044-3050
   Abstract »    Full Text »    PDF »
Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution..
W.-C. Chou, J.-L. Tang, L.-I. Lin, M. Yao, W. Tsay, C.-Y. Chen, S.-J. Wu, C.-F. Huang, R.-J. Chiou, M.-H. Tseng, et al. (2006)
Cancer Res. 66, 3310-3316
   Abstract »    Full Text »    PDF »
c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma.
M. P. Oyarzo, L. J. Medeiros, C. Atwell, M. Feretzaki, V. Leventaki, E. Drakos, H. M. Amin, and G. Z. Rassidakis (2006)
Blood 107, 2544-2547
   Abstract »    Full Text »    PDF »
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.
R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. (2006)
Blood 107, 689-697
   Abstract »    Full Text »    PDF »
Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells.
J. Y. Gouzi, C. Moog-Lutz, M. Vigny, and N. Brunet-de Carvalho (2005)
J. Cell Sci. 118, 5811-5823
   Abstract »    Full Text »    PDF »
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
R. G. W. Verhaak, C. S. Goudswaard, W. van Putten, M. A. Bijl, M. A. Sanders, W. Hugens, A. G. Uitterlinden, C. A. J. Erpelinck, R. Delwel, B. Lowenberg, et al. (2005)
Blood 106, 3747-3754
   Abstract »    Full Text »    PDF »
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.
C. Ambrogio, C. Voena, A. D. Manazza, R. Piva, L. Riera, L. Barberis, C. Costa, G. Tarone, P. Defilippi, E. Hirsch, et al. (2005)
Blood 106, 3907-3916
   Abstract »    Full Text »    PDF »
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
N. Boissel, A. Renneville, V. Biggio, N. Philippe, X. Thomas, J.-M. Cayuela, C. Terre, I. Tigaud, S. Castaigne, E. Raffoux, et al. (2005)
Blood 106, 3618-3620
   Abstract »    Full Text »    PDF »
Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability.
E. Colombo, P. Bonetti, E. Lazzerini Denchi, P. Martinelli, R. Zamponi, J.-C. Marine, K. Helin, B. Falini, and P. G. Pelicci (2005)
Mol. Cell. Biol. 25, 8874-8886
   Abstract »    Full Text »    PDF »
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
T. Suzuki, H. Kiyoi, K. Ozeki, A. Tomita, S. Yamaji, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, et al. (2005)
Blood 106, 2854-2861
   Abstract »    Full Text »    PDF »
Activation of {alpha}-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase.
R. Bacchiocchi, G. Baldanzi, D. Carbonari, C. Capomagi, E. Colombo, W. J. van Blitterswijk, A. Graziani, and F. Fazioli (2005)
Blood 106, 2175-2182
   Abstract »    Full Text »    PDF »
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.
G. Cazzaniga, M. G. Dell'Oro, C. Mecucci, E. Giarin, R. Masetti, V. Rossi, F. Locatelli, M. F. Martelli, G. Basso, A. Pession, et al. (2005)
Blood 106, 1419-1422
   Abstract »    Full Text »    PDF »
Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin.
C. Moog-Lutz, J. Degoutin, J. Y. Gouzi, Y. Frobert, N. B.-d. Carvalho, J. Bureau, C. Creminon, and M. Vigny (2005)
J. Biol. Chem. 280, 26039-26048
   Abstract »    Full Text »    PDF »
Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma.
Y. Osajima-Hakomori, I. Miyake, M. Ohira, A. Nakagawara, A. Nakagawa, and R. Sakai (2005)
Am. J. Pathol. 167, 213-222
   Abstract »    Full Text »    PDF »
BEST PRACTICE No 185 Cytological and molecular diagnosis of lymphoma.
G Kocjan (2005)
J. Clin. Pathol. 58, 561-567
   Abstract »    Full Text »    PDF »
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype.
B. Falini, C. Mecucci, E. Tiacci, M. Alcalay, R. Rosati, L. Pasqualucci, R. La Starza, D. Diverio, E. Colombo, A. Santucci, et al. (2005)
N. Engl. J. Med. 352, 254-266
   Abstract »    Full Text »    PDF »
NPM Mutations in Acute Myelogenous Leukemia.
S. Grisendi and P. P. Pandolfi (2005)
N. Engl. J. Med. 352, 291-292
   Full Text »    PDF »
Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.
G. Z. Rassidakis, M. Feretzaki, C. Atwell, I. Grammatikakis, Q. Lin, R. Lai, F.-X. Claret, L. J. Medeiros, and H. M. Amin (2005)
Blood 105, 827-829
   Abstract »    Full Text »    PDF »
Two Decades of Cancer Genetics: From Specificity to Pleiotropic Networks.
S. GRISENDI and P.P. PANDOLFI (2005)
Cold Spring Harb Symp Quant Biol 70, 83-91
   Abstract »    PDF »
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone (2005)
Blood 105, 22-30
   Abstract »    Full Text »    PDF »
Peroxisome proliferator-activated receptor {gamma} and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
M. Konopleva, E. Elstner, T. J. McQueen, T. Tsao, A. Sudarikov, W. Hu, W. D. Schober, R.-Y. Wang, D. Chism, S. M. Kornblau, et al. (2004)
Mol. Cancer Ther. 3, 1249-1262
   Abstract »    Full Text »    PDF »
A directed screen for genes involved in Drosophila blood cell activation.
C.-J. Zettervall, I. Anderl, M. J. Williams, R. Palmer, E. Kurucz, I. Ando, and D. Hultmark (2004)
PNAS 101, 14192-14197
   Abstract »    Full Text »    PDF »
Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes.
B. Martinez-Delgado, B. Melendez, M. Cuadros, J. Alvarez, J. M. Castrillo, A. Ruiz de la Parte, M. Mollejo, C. Bellas, R. Diaz, L. Lombardia, et al. (2004)
Clin. Cancer Res. 10, 4971-4982
   Abstract »    Full Text »    PDF »
Subcellular Localization of Immunohistochemical Signals: Knowledge of the Ultrastructural or Biologic Features of the Antigens Helps Predict the Signal Localization and Proper Interpretation of Immunostains.
W. Cheuk and J. K. C. Chan (2004)
International Journal of Surgical Pathology 12, 185-206
   Abstract »    PDF »
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.
A. Motegi, J. Fujimoto, M. Kotani, H. Sakuraba, and T. Yamamoto (2004)
J. Cell Sci. 117, 3319-3329
   Abstract »    Full Text »    PDF »
Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma.
G. Z. Rassidakis, R. Lai, M. Herling, C. Cromwell, A. Schmitt-Graeff, and L. J. Medeiros (2004)
Am. J. Pathol. 164, 2259-2267
   Abstract »    Full Text »    PDF »
Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin: Role of the Co-Chaperone Carboxyl Heat Shock Protein 70-Interacting Protein.
P. Bonvini, H. D. Rosa, N. Vignes, and A. Rosolen (2004)
Cancer Res. 64, 3256-3264
   Abstract »    Full Text »    PDF »
Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma.
E. J. Schlette, L. J. Medeiros, A. Goy, R. Lai, and G. Z. Rassidakis (2004)
J. Clin. Oncol. 22, 1682-1688
   Abstract »    Full Text »    PDF »
Origins, Lineage-Specific Expansions, and Multiple Losses of Tyrosine Kinases in Eukaryotes.
S.-H. Shiu and W.-H. Li (2004)
Mol. Biol. Evol. 21, 828-840
   Abstract »    Full Text »    PDF »
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
S. Trudel, S. Ely, Y. Farooqi, M. Affer, D. F. Robbiani, M. Chesi, and P. L. Bergsagel (2004)
Blood 103, 3521-3528
   Abstract »    Full Text »    PDF »
Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
D. Cussac, C. Greenland, S. Roche, R.-Y. Bai, J. Duyster, S. W. Morris, G. Delsol, M. Allouche, and B. Payrastre (2004)
Blood 103, 1464-1471
   Abstract »    Full Text »    PDF »
Utility of Linearly Amplified RNA for RT-PCR Detection of Chromosomal Translocations: Validation Using the t(2;5)(p23;q35) NPM-ALK Chromosomal Translocation.
J. A. Schumacher, S. D. Jenson, K. S. J. Elenitoba-Johnson, and M. S. Lim (2004)
J. Mol. Diagn. 6, 16-21
   Abstract »    Full Text »
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, V. S. Lestou, N. L. Harris, H.-K. Muller-Hermelink, J. F. Seymour, L. J. Campbell, D. E. Horsman, I. Auvigne, et al. (2003)
Blood 102, 2568-2573
   Abstract »    Full Text »    PDF »
ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.
M. Onciu, F. G. Behm, J. R. Downing, S. A. Shurtleff, S. C. Raimondi, Z. Ma, S. W. Morris, W. Kennedy, S. C. Jones, and J. T. Sandlund (2003)
Blood 102, 2642-2644
   Abstract »    Full Text »    PDF »
Complex Genomic Rearrangement of ALK Loci Associated with Integrated Human Epstein-Barr Virus in a Post-Transplant Myogenic Liver Tumor.
M. Debiec-Rychter, R. Croes, R. De Vos, P. Marynen, T. Roskams, A. Hagemeijer, R. Lombaerts, and R. Sciot (2003)
Am. J. Pathol. 163, 913-922
   Abstract »    Full Text »    PDF »
Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK+ and ALK- Anaplastic Large Cell Lymphoma.
J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis, M. A. Yared, P. Tsioli, V. Leventaki, A. Schmitt-Graeff, M. Herling, H. M. Amin, and R. Lai (2003)
Clin. Cancer Res. 9, 3692-3699
   Abstract »    Full Text »    PDF »
Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA).
T. Ouyang, R.-Y. Bai, F. Bassermann, C. von Klitzing, S. Klumpen, C. Miething, S. W. Morris, C. Peschel, and J. Duyster (2003)
J. Biol. Chem. 278, 30028-30036
   Abstract »    Full Text »    PDF »
Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma.
G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles (2003)
Clin. Cancer Res. 9, 2213-2220
   Abstract »    Full Text »    PDF »
5'-(RACE) Identification of Rare ALK Fusion Partner in Anaplastic Large Cell Lymphoma.
N. S. Reading, S. D. Jenson, J. K. Smith, M. S. Lim, and K. S. J. Elenitoba-Johnson (2003)
J. Mol. Diagn. 5, 136-140
   Full Text »    PDF »
Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma.
G. Z. Rassidakis, F.-X. Claret, R. Lai, Q. Zhang, A. H. Sarris, T. J. McDonnell, and L. J. Medeiros (2003)
Clin. Cancer Res. 9, 1121-1128
   Abstract »    Full Text »    PDF »
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
R. Chiarle, J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, et al. (2003)
Blood 101, 1919-1927
   Abstract »    Full Text »    PDF »
Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review.
V Costes-Martineau, C Delfour, S Obled, L Lamant, G-P Pageaux, P Baldet, P Blanc, and G Delsol (2002)
J. Clin. Pathol. 55, 868-871
   Abstract »    Full Text »    PDF »
Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase.
E. T. Bowden, G. E. Stoica, and A. Wellstein (2002)
J. Biol. Chem. 277, 35862-35868
   Abstract »    Full Text »    PDF »
Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma.
J. L. Kutok and J. C. Aster (2002)
J. Clin. Oncol. 20, 3691-3702
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)